ATE225405T1 - Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit - Google Patents
Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheitInfo
- Publication number
- ATE225405T1 ATE225405T1 AT99401742T AT99401742T ATE225405T1 AT E225405 T1 ATE225405 T1 AT E225405T1 AT 99401742 T AT99401742 T AT 99401742T AT 99401742 T AT99401742 T AT 99401742T AT E225405 T1 ATE225405 T1 AT E225405T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- preventing
- prognosis
- diagnosis
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 abstract 5
- 101710115418 Apolipoprotein(a) Proteins 0.000 abstract 5
- 101150037123 APOE gene Proteins 0.000 abstract 3
- 108700028369 Alleles Proteins 0.000 abstract 3
- 102100029470 Apolipoprotein E Human genes 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99401742A EP1074634B1 (de) | 1999-07-09 | 1999-07-09 | Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE225405T1 true ATE225405T1 (de) | 2002-10-15 |
Family
ID=8242047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99401742T ATE225405T1 (de) | 1999-07-09 | 1999-07-09 | Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1074634B1 (de) |
| JP (1) | JP2003504606A (de) |
| AT (1) | ATE225405T1 (de) |
| AU (1) | AU6823600A (de) |
| DE (1) | DE69903278D1 (de) |
| WO (1) | WO2001004349A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| GB0200757D0 (en) * | 2002-01-15 | 2002-02-27 | Univ Manchester | Diagnostic methods |
| AU2004238146A1 (en) * | 2003-05-16 | 2004-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Preventive and/or remedy for diseases accompanied by tissue destruction |
| WO2005080594A2 (en) | 2004-02-24 | 2005-09-01 | Innogenetics N.V. | Method for determining the risk of developing a neurological disease |
| DK1919290T3 (da) | 2005-07-12 | 2014-04-22 | Ampio Pharmaceuticals Inc | Fremgangsmåder og produkter til behandling af sygdomme |
| WO2007092380A2 (en) * | 2006-02-06 | 2007-08-16 | Berkeley Heartlab, Inc. | Apolipoprotein e genotyping and accompanying internet-based health management system |
| HRP20130123T1 (hr) | 2009-06-22 | 2013-03-31 | Dmi Acquisition Corp. | Postupak lijeäśenja bolesti |
| CN104968350A (zh) | 2012-12-19 | 2015-10-07 | 安皮奥制药股份有限公司 | 疾病的治疗方法 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング,インコーポレイテッド | Tim-3とそのリガンドとの相互作用の遮断によるがん治療 |
| CN108346468B (zh) * | 2017-12-27 | 2021-03-23 | 北京科迅生物技术有限公司 | 数据处理方法及装置 |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング,インコーポレイテッド | ガレクチン-3を遮断することにより炎症性疾患を処置する方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2716894B1 (fr) * | 1994-03-07 | 1996-05-24 | Pasteur Institut | Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic. |
| US5599706A (en) * | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| US5773432A (en) * | 1996-10-30 | 1998-06-30 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
-
1999
- 1999-07-09 EP EP99401742A patent/EP1074634B1/de not_active Expired - Lifetime
- 1999-07-09 DE DE69903278T patent/DE69903278D1/de not_active Expired - Lifetime
- 1999-07-09 AT AT99401742T patent/ATE225405T1/de not_active IP Right Cessation
-
2000
- 2000-07-07 AU AU68236/00A patent/AU6823600A/en not_active Abandoned
- 2000-07-07 WO PCT/EP2000/006730 patent/WO2001004349A2/en not_active Ceased
- 2000-07-07 JP JP2001509549A patent/JP2003504606A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001004349A2 (en) | 2001-01-18 |
| DE69903278D1 (de) | 2002-11-07 |
| AU6823600A (en) | 2001-01-30 |
| WO2001004349A3 (en) | 2001-05-25 |
| EP1074634B1 (de) | 2002-10-02 |
| JP2003504606A (ja) | 2003-02-04 |
| EP1074634A1 (de) | 2001-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE269978T1 (de) | Verfahren zur bestimmung der prognose eines patienten mit einer neurologischen krankheit | |
| ATE225405T1 (de) | Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit | |
| WO2003016494A3 (en) | Diagnosis and treatment of vascular disease | |
| Ichikawa et al. | Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations | |
| FI951701A0 (fi) | Menetelmät Alzheimerin taudin tunnistamiseksi | |
| Dixon et al. | Identical mutations in NOG can cause either tarsal/carpal coalition syndrome or proximal symphalangism | |
| EP1556405A4 (de) | Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert | |
| ATE546734T1 (de) | Risikomarker für eine herzkreislaufkrankheit | |
| DK0991421T3 (da) | Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom | |
| FI964284A0 (fi) | Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito | |
| Rozycka et al. | Evidence for S284L mutation of the CHRNA4 in a white family with autosomal dominant nocturnal frontal lobe epilepsy | |
| DE60325617D1 (de) | Verfahren zur diagnose von bauchspeicheldrüsenkrebs | |
| WO2003089897A3 (en) | Diagnosis and treatment of vascular disease | |
| EE200100472A (et) | Polüpeptiid, antikehad, lahustuv polüpeptiid, polü- või oligonukleotiid ja meetod diferentsiaalseltekspresseerunud DNA järjestuste spetsiifiliseks identifitseerimiseks | |
| Qiu et al. | Lack of association between the promoter polymorphism of the MTNR1A gene and adolescent idiopathic scoliosis | |
| WO2003020118A3 (en) | Diagnosis and treatment of vascular disease | |
| ATE169343T1 (de) | Gemeinschaftlich verwendete genetische marker zur diagnostik der alzheimerschen krankheit, methode und diagnostischer reagenziensatz | |
| DE60016405D1 (de) | Neurodegenerative-erkrankung verwandtes gen | |
| DE60231222D1 (de) | Herz-kreislauf-erkrankung vorhersagende einzelnukleotid-polymorphismen | |
| ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
| Naeem et al. | A mutation in CTSK gene in an autosomal recessive pycnodysostosis family of Pakistani origin | |
| Boschann et al. | Biallelic variants in ADAMTS15 cause a novel form of distal arthrogryposis | |
| FR2773079B1 (fr) | Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii | |
| FI20040227A7 (fi) | Menetelmä syövän, sepelvaltimotaudin ja aivohalvauksen riskin havaitsemiseksi | |
| DE60314497D1 (de) | Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |